CAMERA-MRI II
Research type
Research Study
Full title
Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Systolic Heart Failure and Myocardial Fibrosis – an MRI guided Multi-Centre Randomised Controlled Trial
IRAS ID
329602
Contact name
Manish Kalla
Contact email
Sponsor organisation
Alfred Hospital
Clinicaltrials.gov Identifier
ACTRN12620000502932, ANZCTR
Duration of Study in the UK
0 years, 11 months, 1 days
Research summary
Atrial fibrillation (AF) and heart failure (HF) are increasingly prevalent and commonly co-exist. AF is the most common arrhythmia worldwide and may cause or exacerbate HF. A proportion of patients will demonstrate improvements in heart failure symptoms and heart function with restoration to normal rhythm achieved via catheter ablation (CA). CA (the most effective therapy in treating AF) is a minimally invasive procedure to eliminate AF. However, due to the different types of HF, it is important to assess which patients may benefit better from restoration to normal rhythm. Few studies have used heart MRI (CMR) to assess the impact of scarring in heart muscle of the main pumping chamber (left ventricular,LV) on success of CA in AF and HF. Furthermore, while CA is a mainstream treatment for AF, its application in patients with HF remains incompletely understood. The CAMERA-MRI II study will build upon the earlier CAMERA-MRI study, by including all patients with HF and AF. This study will utilise CMR to assess how the heart muscle scarring affects on patients having CA versus medications only. (180/300)
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
23/NW/0380
Date of REC Opinion
13 Feb 2024
REC opinion
Further Information Favourable Opinion